期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

表皮生长因子受体酪氨酸激酶抑制剂联合化疗治疗肺癌的研究进展

Advances in epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment
原文传递
导出
摘要 表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（EGFR—TKI）对EGFR突变肺癌患者表现出很好的疗效，对于EGFR野生型肺癌患者化疗药物是首选，EGFR-TKI和化疗药物联合在基础研究方面表现出良好的协同作用，而在临床研究方面与其两药联合的时序有关。 Epidermal growth factor receptor tyrosine kinase inhibitors （EGFR-TKIs） show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.
作者 张贝贝 宋正波 张沂平
机构地区 浙江省肿瘤医院化疗中心
出处 《国际肿瘤学杂志》 CAS 2013年第7期526-529,共4页 Journal of International Oncology
基金 吴阶平医学基金（320.6750.11059,320.6750.11091）卫生部医药卫生科技发展研究中心课题（W2012FZ134） 浙江省自然科学基金（LY13H0160024）
关键词 受体 表皮生长因子 药物疗法 肺肿瘤 Receptor, epidermal growth factor Drug therapy Lung neoplasms
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Favaretto AG,Pasello G,Magro C.Second and third line treatment in advanced non-small cell lung cancer.Discov Med,2009,8 (43):204-209.
  • 2Fukuoka M,Wu YL,Thongprasert S,et al.Biomarker analyses and final overall survival results from a phase Ⅲ,randomized,openlabel,first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).J Clin Oncol,2011,29 (21):2866-2867.
  • 3Shepherd FA,Rodrigues PJ,Ciuleanu T,et al.Erlotinib in previously treated non-small-cell lung cancer,N Engl J Med,2005,353 (2):123-132.
  • 4郑直,曲延征.化疗药物诱导细胞凋亡机制的研究进展[J].福建医药杂志,2007,29(2):95-97. 被引量：3
  • 5Okabe T,Okamoto I,Tsukioka S,et al.Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines:role of gefitinib-induced downregulation of thymidylate synthase.Mol Cancer Ther,2008,7 (3):599-606.
  • 6Van Schaeybroeck S,Kyula J,Kelly DM,et al.Chemotherapyinduced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.Mol Cancer Ther,2006,5 (5):1154-1165.
  • 7Giovannetti E,Lemos C,Tekle C,et al.Molecular mechanisms underlying the synergistic interaction of erlotinib,an epidermal growth factor receptor tyrosine kinase inhibitor,with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.Mol Pharmacol,2008,73 (4):1290-1300.
  • 8Cheng H,An S J,Dong S,Zhang YF,et al.Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant nonsmall cell lung cancer cell lines treated with paclitaxel and gefitinib.J Hematol Oncol,2011,4:5.
  • 9张文颖,张为民,王林,郑静娴,肖锋.多西他赛与吉非替尼序贯应用对人肺腺癌细胞SPC-A1生长及信号蛋白的影响[J].中国肺癌杂志,2011,14(5):385-390. 被引量：9
  • 10J(a)nne PA,Wang X,Socinski MA,et al.Randomized phase Ⅱ trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced ltng adenocarcinoma:CALGB 30406 trial.J Clin Oncol,2012,30(17):2063-2069.

二级参考文献36

  • 1霍伟,冯仲珉,赵卫红,张咏梅,刘晓丹,董华承.吉非替尼治疗晚期非小细胞肺癌64例[J].临床肿瘤学杂志,2005,10(1):4-7. 被引量：23
  • 2潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量：44
  • 3Brekken RA ,Thorpe PE. Vascular endothelial growth factor and vascular targetin of solid tumors[ J]. Anticancer Res,2001 ;21 (6B) :4221-49.
  • 4Thatcher N,Chang A,Parikh P,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer( Results from a randomized, placebo-controlled, multicentre study oressa Survival Evaluation in Lung Cancer ) [ J ] . Lancet, 2005 ; 366 ( 9496 ) : 1527-37.
  • 5Shepherd FA, Rodrigues P J, Ciuleanu T, et al. Erlotinib inpreviously treated non-small-cell lung cancer[ J ].N Engl J Med,2005 ;353 (2):123- 32.
  • 6Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum- doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non- small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).J Clin Oncol, 2008, 28(5): 753-760.
  • 7Lee JS, Ignacio J, Yu C, et al. FAST-ACT: A phase II randomized double- blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-smaU cell lung cancer (NSCLC). J Clin Oncol, 2008, 26(15): 8031-8040.
  • 8Munster PNj Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy induced poptosis in an RB- and schedule-dependentmanner. Clin Cancer Res, 2001, 7(8): 2228-2236.
  • 9Van Schaeybroeck S, Kyula J, Kelly DM, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther, 2006, 5 (5): 1154-1165.
  • 10Morgillo F, Woo JK, Kim ES, et al. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of surviving expression counteract the antitumor action of erlotinib. Cancer Res, 2006, 66(20): 10100-10111.

共引文献13

国际肿瘤学杂志
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部